CytomX Therapeutics is leaning hard on a lead cancer drug that aims to hit tumors while sparing the rest of the body, but the next clinical readouts could expose safety and effectiveness limits that slow its path forward. The company also has earlier programs and big partners in the background, yet the long timelines and crowded cancer space may mean more waiting—and possible fundraising—before the longer-term promise shows up.Read more
CytomX is betting that its tumor-targeted drug platform can make existing cancer medicines work in more patients, with early signs that its lead programs could reach beyond the groups most people expect. The big question is whether the next trial results and partner support show the approach is safe and effective enough to turn a research-heavy story into a real business.Read more
CytomX is betting that its tumor-targeting drug approach can deliver strong cancer treatment results while avoiding the side effects that often limit older therapies. Early patient data looks promising, but safety concerns, uncertain approvals, and reliance on partners mean the path ahead could still get rocky.Read more
No trending discussion available.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company’s development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
